Perioperative antiplatelet therapy.
Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease.
Mon Feb 24, 2014
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against The Medicines Company
The Complaint that defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.
Fri Feb 21, 2014
Pomerantz Law Firm Announces the Filing of a Class Action Against The ...
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10 and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
New Market Research Report: Arch Pharmalabs Ltd. - Pharmaceuticals &...
The company manufactures and supplies various generic APIs and pharmaceutical intermediates for pharmaceutical players in both domestic and international markets.
Thu Feb 20, 2014
Computer simulation shows that knowing patients' genetic profiles can save money, improve outcomes
Genetic testing can help doctors choose the most effective and economical drugs to prevent blood clots in the half a million patients in the U.S. who receive coronary stents each year, according to a new study led by a UC San Francisco researcher.
Tue Feb 18, 2014
Duration of dual antiplatelet therapy following percutaneous coronary ...
The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention remains uncertain.
Wed Feb 12, 2014
FDA panel votes against approval of Medicines Co's blood clot preventer
An independent advisory panel to the U.S. Food and Drug Administration said a blood clot preventer developed by The Medicines Co should not be approved due to a lack of data to prove its efficacy.
FDA Advisory Panel Recommends Against Approval Of New Medicines Company Heart Drug
The FDA's Cardiovascular and Renal Drugs Advisory Committee today recommended against the approval of cangrelor, the investigational new antiplatelet drug from the Medicines Company.
Mon Feb 10, 2014
FDA Committee Issues Mixed Opinions on Blood Clot Drug Cangrelor
Members of the FDA's Cardiovascular and Renal Drugs Advisory Committee are divided on whether cangrelor , an intravenous anticoagulant, should receive marketing approval.
UPDATE 1-FDA staff offer mixed view of Medicines Co's blood clot drug
U.S. Food and Drug Administration reviewers are divided on whether an intravenous blood clot preventer developed by The Medicines Co should be approved, news that sent the company's stock down more than 7 percent on Monday.